ReviewExperientia supplementum (2012)2026
Noncoding RNAs in Metabolic Reprogramming of Breast Cancer: Dietary Opportunities and Translational Implications.
Review in Experientia supplementum (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lipid metabolism reprogramming: key mechanism of breast cancer endocrine therapy resistance.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains one of the leading causes of cancer-related death among women worldwide, characterized by significant molecular and metabolic heterogeneity. Metabolic reprogramming has been shown to enable tumor cells to adapt to the dynamic microenvironment, supporting uncontrolled proliferation and survival. Emerging evidence highlights the critical roles of noncoding RNAs (ncRNAs), including microRNAs, long noncoding RNAs, and circular RNAs, in coordinating the complex regulatory networks underlying metabolic reprogramming in breast cancer. These ncRNAs influence key metabolic pathways such as glycolysis, lipid metabolism, and amino acid metabolism by targeting transcription factors, enzymes, and signaling cascades. Evidence suggests that targeting dysregulated ncRNAs holds significant potential for modulating cancer cell metabolism and offers novel strategies for breast cancer management. Furthermore, bioactive compounds derived from dietary sources have demonstrated the ability to modulate ncRNA expression and function, presenting exciting prospects for dietary or nutritional interventions in breast cancer therapy. This chapter compiles the intricate relationship between ncRNAs and metabolic reprogramming in breast cancer, with a focus on innovative techniques to target ncRNAs and the potential of dietary strategies to influence these regulatory pathways.
Indexed as
Identifiers
41479118What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.